Inflammation 2002-04-01

Early vascular permeability in murine experimental peritonitis is co-mediated by resident peritoneal macrophages and mast cells: crucial involvement of macrophage-derived cysteinyl-leukotrienes.

Elzbieta Kolaczkowska, Susan Shahzidi, Rolf Seljelid, Nico van Rooijen, Barbara Plytycz

Index: Inflammation 26(2) , 61-71, (2002)

Full Text: HTML

Abstract

The initial phase of zymosan-induced peritonitis involves an increase of vascular permeability (peak at 30 min) that is correlated with high levels of vasoactive eicosanoids, namely, prostaglandins (PGI2 and PGE2) of cyclooxygenase-1 origin (as estimated by RT-PCR) and cysteinyl-leukotrienes. Previously, we showed that the increase of vascular permeability can be attributed only partially to mast cells and their histamine, as seen in mast cell-deficient WBB6F1-W/Wv mice. Thus we aimed to identify the major cellular source(s) that mediate vasopermeability, as well as particular vasoactive mediators operating in this model. For this purpose, some mice were selectively depleted of either peritoneal macrophages or mast cells, and/or they were treated with several pharmacologic inhibitors of cyclooxygenase- and lipoxygenase-metabolic pathways. More-over, macrophage-depleted mast cell-deficient WBB6F1-W/Wv mice and their controls (+/+) were used. The macrophage depletion always caused a profound decrease of both vascular permeability and lipid-mediator levels, which was particularly pronounced for leukotrienes, whereas the effects of mast-cell depletion were less severe. The macrophage/mast-cell co-mediation of vasopermeability was also revealed in thioglycolate-induced peritonitis, as well as the macrophage origin of cysteinyl-leukotrienes. Taken together, these findings demonstrate that the resident peritoneal macrophages are in fact the main contributors to the vasopermeability at the early stages of zymosan-induced peritonitis.


Related Compounds

Related Articles:

Actions of cysteinyl leukotrienes in the enteric nervous system of guinea-pig stomach and small intestine.

2003-01-10

[Eur. J. Pharmacol. 459(1) , 27-39, (2003)]

Enhanced activity of Ca2+-activated K+ channels by 1-[2-hydroxy-3-propyl-4-[(1H-tetrazol-5-yl)butoxyl]phenyl] ethanone (LY-171883) in neuroendocrine and neuroblastoma cell lines.

2002-08-01

[J. Cell Physiol. 192(2) , 188-99, (2002)]

Control of chondrocyte regulatory volume decrease (RVD) by [Ca2+]i and cell shape.

2008-03-01

[Osteoarthr. Cartil. 16(3) , 312-22, (2008)]

A new class of leukotriene biosynthesis inhibitor: the development of MK-0591.

1993-01-01

[J. Lipid Mediat. 6(1-3) , 239-44, (1993)]

Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits.

1992-12-01

[Br. J. Pharmacol. 107(4) , 1108-15, (1992)]

More Articles...